MYMETICS CORP
MYMETICS CORP (MYMX): 8 pipeline candidates · ~1 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
0.7 months
D/E -1.00 · 0% dilution
Lead: Phase 1
8 candidates
N/A
N/A
A transparent, data-derived signal for MYMETICS CORPacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$45
Cash
$62K
Quarterly Burn
$335K
Runway
0.7 mo
Revenue
$34K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (8 candidates)
| Drug | Phase |
|---|---|
| birch pollen allergy immunotherapy | Preclinical |
| covid-19 vaccine | Preclinical |
| hiv-1 vaccine | Phase 1 |
| hsv vaccine | Preclinical |
| intranasal influenza vaccine | Phase 1 |
| malaria vaccine | Phase 1 |
| mym-v101 | Phase 1 |
| rsv vaccine | Preclinical |
Frequently asked questions
How many drug candidates are in MYMETICS CORP's pipeline?
MYMETICS CORP (MYMX) has 8 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is MYMETICS CORP's lead drug candidate?
MYMETICS CORP's most advanced tracked candidate is birch pollen allergy immunotherapy (Preclinical) for Birch pollen allergy.
What is MYMETICS CORP's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, MYMETICS CORP has approximately 0.7 months of cash runway.
What is MYMETICS CORP's market capitalization?
MYMETICS CORP's market capitalization is approximately $45.
Get the full picture on MYMETICS CORP
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.